ClinicalTrials.gg
CompletedNCT06181786Updated Jun 17, 2025

Study of NAV-240 in Healthy Volunteers

A Phase 1 interventional study of NAV-240 and Placebo in Healthy, sponsored by Navigator Medicines, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-06-17.

Sponsored by Navigator Medicines, Inc. · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Sep 2024, 2 years 2 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The primary purpose of this study is to evaluate the safety and tolerability of intravenous (IV) doses of NAV-240 in healthy volunteers.

02

Conditions studied

  • Healthy

Keywords

  • Pharmacokinetics
  • IMB-101
  • OX40L/TNF bispecific antibody
  • NAV-240
03

In context

Lead sponsor

Navigator Medicines, Inc. is the lead sponsor of 3 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  1. The participant is 18 to 55 years of age, inclusive, at screening.
  2. The participant has a of 18.5 to ≤ 32 kg/m\^2 at screening.
  3. The participant is considered by the investigator to be in good general health as determined by medical history, clinical laboratory test results, vital sign measurements, 12-lead results, and physical examination findings not at screening.
  4. Female participants of must use at least 1 form of highly effective methods of from screening until at least 90 days after last study drug dose; OR be surgically sterile OR be . All female participants of childbearing potential must have a negative pregnancy test at screening and before the first dose of study drug. Female participants must also agree to refrain from egg donation during the study and for at least 90 days after study drug dosing.
  5. Male participants must agree to use a condom when sexually active with a female partner of childbearing potential during the study and for at least 90 days after study drug dosing (OR be surgically sterile; OR agree to practice abstinence during the study and for at least 90 days after study drug dosing).
  6. The participant agrees to comply with all protocol requirements.
  7. The participant is able to provide written .

Key Exclusion Criteria:

  1. The participant has any significant acute or chronic medical illness that, in the opinion of the investigator, would impact the participant's ability to complete all study requirements or that might impact the assessment of study data; or the participant has had a clinically significant illness within 30 days prior to study drug dosing per investigator discretion.
  2. The participant has a positive COVID-19 molecular diagnostic test result at screening or prior to study drug dosing; or the participant has known or suspected current sequelae from a prior episode of COVID-19.
  3. The participant has had major surgery, as determined by the investigator, within 12 weeks prior to study drug dosing.
  4. The participant has any of the following prior to study drug dosing:

    • Systolic blood pressure >140 mmHg and/or diastolic blood pressure >90 mmHg.
  5. The participant has any of the following on 12-lead ECG prior to study drug dosing, confirmed by repeat:

    • Heart rate \<40 or >100 beats per minute.
    • PR interval >220 milliseconds (ms).
    • QRS width >120 ms.
    • >=450 ms (male) or >=470 ms (female).
  6. The participant has any of the following clinical laboratory results at screening, confirmed by repeat:

    • WBCs, lymphocytes, or outside site acceptable ranges per site SOPs.
    • \< 60 mL/min/1.73m\^2 (the CKD-EPI formula)
    • or AST >2*
    • Total >2*ULN
  7. The participant has a positive test result for , anti-HBcAb, virus antibody, or types 1 or 2 antibodies at screening.
  8. The participant has a history of TB, active TB, or a positive Quantiferon-TB Gold Plus (QFT-Plus) test at screening.
  9. The participant has received any vaccine or used any prescription or over the-counter medications (except acetaminophen [up to 2 g per day]), including herbal or nutritional supplements, within 14 days prior to study drug dosing.
  10. The participant has received biologic agents within the 3 months prior to study drug dosing, or 5 half-lives, whichever is greater. Participants with a prior history of anti-TNFα exposure will be excluded.
  11. The participant is a smoker or has regularly used nicotine or nicotine-containing products within 3 months prior to study drug dosing.
  12. History of drug abuse within 1 year prior to screening.
  13. The participant has a positive test result for drugs of abuse, alcohol, or cotinine (indicating active current smoking) at screening or prior to study drug dosing.
  14. The participant has donated blood or blood products >500 mL within 30 days prior to study drug dosing.
  15. The participant has a history of to vaccines, the study drug, or to drugs of similar chemical classes including allergy to drug or its .
  16. Any reason which, in the opinion of the Investigator, would prevent the participant from participating in the study.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Single Ascending Doses (SAD) of NAV-240 IV

    Single intravenous (IV) administration of ascending dose levels of NAV-240

    Drug: NAV-240

  • Placebo comparator
    Single Doses of Placebo

    Single intravenous (IV) administration of placebo

    Drug: Placebo

Interventions

  • Intravenous administration of NAV-240

  • DrugPlacebo

    Intravenous administration of matching placebo for NAV-240

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    TEAEs are defined as events that started after the first dose of study treatment or events that presented prior to the first dose of study drug but increased in severity after the first dose based on preferred term, including clinically relevant abnormal laboratory findings. SAEs are defined as any event that either results in death, is immediately life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event.

    Time frame: From the dose of study drug on Day 1 up to Day 71

Secondary outcomes

  1. Maximum Serum Concentration (Cmax) of NAV-240

    Time frame: From Day 1 prior to the first dose of study drug up to Day 71

  2. Time to Maximum Serum Concentration (Tmax) of NAV-240

    Time frame: From Day 1 prior to the first dose of study drug up to Day 71

  3. Area Under the Serum Concentration-Time Curve From Time Zero to 336 hours post-dose (AUC0-336) of NAV-240

    Time frame: From Day 1 prior to the first dose of study drug up to Day 71

  4. Area Under the Serum Concentration-Time Curve from Time Zero to the Concentration at a given Time Point (AUC0-t) of NAV-240

    Time frame: From Day 1 prior to the first dose of study drug up to Day 71

  5. Area Under the Serum Concentration-Time Curve from Time Zero to Infinity (AUC0-inf) of NAV-240

    Time frame: From Day 1 prior to the first dose of study drug up to Day 71

  6. Serum Elimination Half-life (t1/2) of NAV-240

    Time frame: From Day 1 prior to the first dose of study drug up to Day 71

  7. Terminal Elimination Rate Constant (λz) of NAV-240

    Time frame: From Day 1 prior to the first dose of study drug up to Day 71

  8. Apparent Total Body Clearance (CL) of NAV-240

    Time frame: From Day 1 prior to the first dose of study drug up to Day 71

  9. Apparent Volume of Distribution (Vz) of NAV-240

    Time frame: From Day 1 prior to the first dose of study drug up to Day 71

  10. Trough Serum Concentration (Ctrough) of NAV-240

    Time frame: From Day 1 prior to the first dose of study drug up to Day 71

  11. Incidence of Presence of Antidrug Antibodies (ADAs)

    The formation of ADAs against NAV-240 as assessed in blood samples. Proportion of participants with positive or negative results for ADAs.

    Time frame: From the first dose of study drug up to Day 71

  12. ADA Titers in Participants with Positive ADA

    Time frame: From the first dose of study drug up to Day 71

07

Study locations

1 site
  • Syneos Health
    Miami, Florida 33136, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2023 to primary completion in Sep 2024, 9 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 13, 2023
First posted
Dec 26, 2023
StartActual
Nov 22, 2023
Primary completionActual
Sep 4, 2024
CompletionActual
Sep 4, 2024
Last update
Jun 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06181786
Lead sponsor
Navigator Medicines, Inc.
Collaborators
IMBiologics Corp.
Responsible party
Sponsor
First posted
Dec 26, 2023
Start date
Nov 22, 2023
Primary completion
Sep 4, 2024
Completion
Sep 4, 2024
Last update
Jun 17, 2025

Study contacts

Dana McClintock, MD
study director · Navigator Medicines, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: NAV-240

Start the discussion